Ciprofloxacin inhalation - Bayer Healthcare/Novartis

Drug Profile

Ciprofloxacin inhalation - Bayer Healthcare/Novartis

Alternative Names: Bay q 3939; BAYQ3939; Cipro DPI; Cipro inhale; Ciprofloxacin PulmoSphere®; Ciprofloxin inhalation powder programme

Latest Information Update: 06 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer HealthCare; Nektar Therapeutics
  • Developer Bayer HealthCare; Novartis
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections; Bronchiectasis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bronchiectasis; Pneumonia
  • No development reported Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections; Respiratory tract infections

Most Recent Events

  • 01 Oct 2016 Bayer and Novartis completes the phase III RESPIRE-2 trial in Bronchiectasis in USA, Argentina, Brazil, Australia, Austria, Bulgaria, Czech Republic, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Slovakia, South Africa, South Korea, Hong Kong, China, Philippines, Taiwan, Thailand, Turkey, Serbia and Russia (NCT02106832)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pseudomonal-infections in USA (Inhalation, Powder)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Respiratory-tract-infections in Germany (Inhalation, Powder)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top